Bain Capital to Acquire BioAtla for $1.00/Share
Ticker: BCAB · Form: 8-K · Filed: Jun 20, 2025 · CIK: 1826892
Sentiment: bullish
Topics: acquisition, merger, private-equity
TL;DR
Bain Capital is buying BioAtla for $1/share cash, deal expected Q3.
AI Summary
BioAtla, Inc. announced on June 17, 2025, that it has entered into a definitive agreement to be acquired by an affiliate of Bain Capital Life Sciences for $1.00 per share in cash. This transaction is expected to close in the third quarter of 2025, subject to customary closing conditions.
Why It Matters
This acquisition by Bain Capital at a premium to recent trading prices could provide liquidity for BioAtla shareholders and potentially accelerate the development of its novel antibody-drug conjugate platform.
Risk Assessment
Risk Level: medium — The deal is subject to closing conditions, and the premium offered may not fully compensate for the potential future value of BioAtla's pipeline.
Key Numbers
- $1.00 — Acquisition Price Per Share (Cash consideration offered to BioAtla shareholders.)
- Q3 2025 — Expected Closing Quarter (Timeline for the completion of the acquisition.)
Key Players & Entities
- BioAtla, Inc. (company) — Company being acquired
- Bain Capital Life Sciences (company) — Acquiring entity
- $1.00 (dollar_amount) — Per share acquisition price
FAQ
What is the total value of the acquisition?
The filing does not explicitly state the total value of the acquisition, but it is based on $1.00 per share in cash for all outstanding shares of BioAtla.
Who is acquiring BioAtla?
An affiliate of Bain Capital Life Sciences is acquiring BioAtla.
When is the acquisition expected to close?
The acquisition is expected to close in the third quarter of 2025.
What are the conditions for the acquisition to close?
The acquisition is subject to customary closing conditions.
What is BioAtla's principal executive office address?
BioAtla's principal executive offices are located at 11085 Torreyana Road, San Diego, California, 92121.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 20, 2025 regarding BioAtla, Inc. (BCAB).